In primary prostate adenocarcinoma, PTEN mutation and deep deletion occur in 2% and 18% of cases respectively (Table S1), and the frequency appears to increase in metastatic disease (6% and 26% respectively, Table S3). The gene discussed is PTEN; the disease is metastatic neoplasm.